Scribd Logo
Upload

Welcome to Scribd!

    • 252 views

    RANBAXY

    Uploaded by

    Ranjith Kumar
    Ranbaxy is India's largest pharmaceutical company with a global footprint in 46 countries. It produces generic medicines and has a presence in developed and emerging markets. Ranbaxy has research facilities and manufactures in 7 countries, serving over 125 countries. In 2008, Ranbaxy recorded global sales of $1.5 billion but incurred losses due to foreign exchange rates. Its competitors include Sun Pharma, Cipla, and GlaxoSmithKline. Ranbaxy aims to grow its generics business and specialty segments like biosimilars through organic and acquisition strategies.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd

    RANBAXY

    Uploaded by

    Ranjith Kumar
    252 views5 pages
    Ranbaxy is India's largest pharmaceutical company with a global footprint in 46 countries. It produces generic medicines and has a presence in developed and emerging markets. Ranbaxy has research facilities and manufactures in 7 countries, serving over 125 countries. In 2008, Ranbaxy recorded global sales of $1.5 billion but incurred losses due to foreign exchange rates. Its competitors include Sun Pharma, Cipla, and GlaxoSmithKline. Ranbaxy aims to grow its generics business and specialty segments like biosimilars through organic and acquisition strategies.

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Ranbaxy is India's largest pharmaceutical company with a global footprint in 46 countries. It produces generic medicines and has a presence in developed and emerging markets. Ranbaxy has research facilities and manufactures in 7 countries, serving over 125 countries. In 2008, Ranbaxy recorded global sales of $1.5 billion but incurred losses due to foreign exchange rates. Its competitors include Sun Pharma, Cipla, and GlaxoSmithKline. Ranbaxy aims to grow its generics business and specialty segments like biosimilars through organic and acquisition strategies.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    252 views5 pages

    RANBAXY

    Uploaded by

    Ranjith Kumar
    Ranbaxy is India's largest pharmaceutical company with a global footprint in 46 countries. It produces generic medicines and has a presence in developed and emerging markets. Ranbaxy has research facilities and manufactures in 7 countries, serving over 125 countries. In 2008, Ranbaxy recorded global sales of $1.5 billion but incurred losses due to foreign exchange rates. Its competitors include Sun Pharma, Cipla, and GlaxoSmithKline. Ranbaxy aims to grow its generics business and specialty segments like biosimilars through organic and acquisition strategies.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 5

    RANBAXY

    INTRODUCION:

    Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an


    integrated, research based, international pharmaceutical company, producing a wide range of
    quality, affordable generic medicines, trusted by healthcare professionals and patients across
    geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the
    world. The Company has a global footprint in 46 countries, world-class manufacturing facilities
    in 7 countries and serves customers in over 125 countries.

    In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator
    companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical
    powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies,
    globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will
    emerge stronger in terms of its global reach and in its capabilities in drug development and
    manufacturing.

    MISSION & VISSION:

    Ranbaxy's mission is ‘To become a Research-based International Pharmaceutical Company’. The


    Company is driven by its vision to ‘Achieve significant business in proprietary prescription
    products by 2012 with a strong presence in developed markets’.

    FINANTIAL:

    Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2009, the Company
    recorded Global Sales of US $ 1519 Mn. The Company has a balanced mix of revenues from
    emerging and developed markets that contribute 54% and 39% respectively. In 2009, North
    America, the Company's largest market contributed sales of US $ 397 Mn, followed by Europe
    garnering US $ 269 Mn and Asia clocking sales of around US $ 441 Mn.

    INTERNAL ANALYSIS:

    Ranbaxy Laboratories Limited - SWOT Analysis

    SWOT ANALYSIS
    STRENGTHS

     Low cost of production.


     Efficient technologies for large number of Generics.
     Large pool of skilled technical manpower

    WEAKNESS

     Low technology level of Capital Goods of this section.


     Very low key R&D.
     Very low level of Biotechnology for New Drug Discovery Systems

    OPPORTUNITY:

     Growing attention for health.


     New therapy approaches.
     Globalization
     Growing incomes.
     New diagnoses and new social diseases.

    THREATS

     High Cost of discovering new products and fewer discoveries.


     Stricter registration procedures.
     High entry cost in newer markets.
     High cost of sales and marketing

    In Ranbaxy

    Many Indian companies that perform well in domestic markets have not yet
    expanded to the International arena. Several factors such as lack of confidence,
    lack of technical know how and perhaps lack of resources inhibit leading Indian
    groups to expand their area of activities to other parts of the world. HRM can play
    a crucial role in changing the attitude of the company and its employees in order to
    facilitate entry and presence in the foreign markets. This is effectively illustrated in the case of
    the Indian pharmaceutical giant RANBAXY which succeeded in
    expanding its business internationally due to the single-handed determination of its past CEO,
    Dr. Parvinder Singh, and the manner in which he managed to change the mindset of his
    employees
    Experienced and capable people joined the organisation, promising talent within
    the Company was put through a planned development programme called LEAD.
    These initiatives are designed to further strengthen our core operations and position
    the Company on a stronger footing while experienced and capable people joined
    the organization, promising talent within the Company was put through a planned
    development.

    Other development programs are

    • Total Rewards Strategy


    • Global Appreciate Programme
    • Fun@Work,

    Company Strategies:

    For the year 2009, Ranbaxy has a clear strategy to harness its growth potential in
    emerging markets, rebuild the US business through a series of actions on products
    and facilities; actualize significant revenue upsides through First-to-File and Day-
    1 launches strengthen the product / therapeutic pipeline and look for M&A
    opportunities, complementing our geographic and therapeutic basket. Our focus
    will be to resolve regulatory compliance issues and continue to strengthen cGMP
    across all locations. Besides this, Ranbaxy and Daiichi Sankyo will identify key
    projects to realize synergies at both the front and back ends of the business,
    although, there will be much to contend with, considering that the industry is
    projected to grow at around 5% in 2009.

    Ranbaxy is focused on increasing the momentum in the generics business in its key markets
    through organic and inorganic growth routes. The Company continues to evaluate acquisition
    opportunities in India, emerging and developed markets to strengthen its business and
    competitiveness. Growth is well spread across geographies with focus on emerging markets.
    Ranbaxy has forayed into new specialty therapeutic segments like Bio-similars, Oncology,
    Peptides and Limuses. These new growth areas will add significant depth to the existing product
    pipeline.

    COMPITETORS:

    The pharmaceutical industry is characterized by rapid advances in scientific


    knowledge and ability to discover new drugs. The industry is therefore led by large
    manufacturers and marketers of drugs investing heavily in research &development, having
    clinical testing, marketing and distributing capabilities. Some of the main competitors of
    Ranbaxy are:

    • Sun Pharmaceuticals Industries - It is No. 1 in India in specialty therapy


    areas like psychiatry, neurology, cardiology, gastroenterology, diabetology
    and respiratory.[.It has brands in 30 markets worldwide and also has a
    generic presence in the U.S. with Caraco Pharm Labs, Sun Pharmaceutical
    Industries Inc

    • Cipla - Cipla is a leader in the domestic retail pharmaceutical market. It also


    exports raw materials, intermediates, prescription drugs, over-the-counter
    products, and veterinary products to some 180 countries around the world.
    • Glaxo smith Kline- It is one of the oldest pharma companies in India and with a turnover of
    Rs. 1500 crore is one of the market leaders(market share)
    in India with a share of 6.2 per cent Its main portfolios consists of anti-
    invectives, dermatologicals and pain management drugs
    • Dr.Reddy’s Laboratories It is a global pharmaceutical company with it's
    headquarters in India and a presence in more than 100 countries. In India it
    the biggest drug maker by sales.

    Other competitors areActavis,Sandoz International GmbH; Teva pharmaceuticals,RPG


    Enterprises, , East India Pharmaceutical Works Ltd, Concept Pharmaceuticals Ltd, Khandelwal
    Laboratories Ltd, Dabur India Ltd.

    Conclusion
     Ranbaxy recorded global sales of US$ 1,682 Mn in 2008, a 4% growth over last year.
    Dosage Form sales constituted 93% of global sales during the year as against 94% in
    2007. Overseas markets constituted 80% of the total sales of the Company
     Consistent depreciation of the rupee in 2008 and large exposure of the Company’s
    business to the international markets has resulted in substantial foreign exchange losses
    of Rs.10,856 Mn on forward covers and loans.
     As a prudent measure to stay current in its accounting practices, the Company adopted
    from October 1, 2008, Accounting Standard 30 on “Financial Instruments: Recognition
    and Measurement” issued by the Institute of Chartered Accountants of India. As a result,
    a net loss of Rs. 7,702 Mn was recognized during the year basis the fair value
    measurement principle suggested in the Standard.

     The total number of employees of the Company and its subsidiaries as on


    December 31, 2008 stood at 12,174.
     In view of the losses incurred by the Company, no dividend has been
    declared for the year ended December 31, 2008.
    Suggestions
     The company has incurred loss in current fiscal year; company has to
    make future plans in such a way that it is not repeated.
     The company has expanded globally but the company should take care of
    the domestic market also.
     Investment plan has to be made keeping in mind the objective of the
    company.

    You might also like